BIOMAT Database Logo BIOMAT Database Logo

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease. 2019

Panayotis Kaloyannidis, and Eshrak Al Shaibani, and Ioannis Apostolidis, and Solaf Kanfar, and Khalid Al Anezi, and Hani Al Hashmi
Adults Hematology and Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia. pkaloyannidis@yahoo.gr.

UI MeSH Term Description Entries
D008297 Male Males
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069286 Bortezomib A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. LDP-341,PS 341,PS-341,Velcade,341, PS,LDP 341,LDP341,PS341
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Panayotis Kaloyannidis, and Eshrak Al Shaibani, and Ioannis Apostolidis, and Solaf Kanfar, and Khalid Al Anezi, and Hani Al Hashmi
Ruxolitinib for steroid-refractory acute graft-versus-host disease.
February 2020, Transplant international : official journal of the European Society for Organ Transplantation,
Panayotis Kaloyannidis, and Eshrak Al Shaibani, and Ioannis Apostolidis, and Solaf Kanfar, and Khalid Al Anezi, and Hani Al Hashmi
Beyond ruxolitinib in steroid-refractory acute graft-versus-host disease.
November 2021, British journal of haematology,
Panayotis Kaloyannidis, and Eshrak Al Shaibani, and Ioannis Apostolidis, and Solaf Kanfar, and Khalid Al Anezi, and Hani Al Hashmi
Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease.
April 2021, Bone marrow transplantation,
Panayotis Kaloyannidis, and Eshrak Al Shaibani, and Ioannis Apostolidis, and Solaf Kanfar, and Khalid Al Anezi, and Hani Al Hashmi
Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
May 2022, Pediatric dermatology,
Panayotis Kaloyannidis, and Eshrak Al Shaibani, and Ioannis Apostolidis, and Solaf Kanfar, and Khalid Al Anezi, and Hani Al Hashmi
Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
October 2021, Leukemia research,
Panayotis Kaloyannidis, and Eshrak Al Shaibani, and Ioannis Apostolidis, and Solaf Kanfar, and Khalid Al Anezi, and Hani Al Hashmi
Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center.
April 2018, Bone marrow transplantation,
Panayotis Kaloyannidis, and Eshrak Al Shaibani, and Ioannis Apostolidis, and Solaf Kanfar, and Khalid Al Anezi, and Hani Al Hashmi
Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease.
February 2024, Bone marrow transplantation,
Panayotis Kaloyannidis, and Eshrak Al Shaibani, and Ioannis Apostolidis, and Solaf Kanfar, and Khalid Al Anezi, and Hani Al Hashmi
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
July 2021, The New England journal of medicine,
Panayotis Kaloyannidis, and Eshrak Al Shaibani, and Ioannis Apostolidis, and Solaf Kanfar, and Khalid Al Anezi, and Hani Al Hashmi
Ruxolitinib for steroid-refractory graft-versus-host disease: A case series.
March 2018, Hematological oncology,
Panayotis Kaloyannidis, and Eshrak Al Shaibani, and Ioannis Apostolidis, and Solaf Kanfar, and Khalid Al Anezi, and Hani Al Hashmi
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.
July 2018, Bone marrow transplantation,
Copied contents to your clipboard!